Spots Global Cancer Trial Database for avapritinib
Every month we try and update this database with for avapritinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World | NCT05381753 | Gastrointestina... | Avapritinib Tyrosine kinase... | 18 Years - | CStone Pharmaceuticals | |
| A Drug-drug Interaction Study of Avapritinib and Midazolam | NCT04908176 | Gastrointestina... GIST Non-resectable ... Recurrent or Un... | Avapritinib midazolam | 18 Years - | Blueprint Medicines Corporation | |
| Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | NCT03862885 | GIST | Avapritinib | 16 Years - | Blueprint Medicines Corporation | |
| (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | NCT03465722 | GIST | avapritinib regorafenib | 18 Years - | Blueprint Medicines Corporation | |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | NCT04771520 | Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Metastatic Prim... Metastatic Sarc... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Prognostic Stag... Prognostic Stag... Stage IIIC Colo... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color... | Avapritinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors | NCT05464875 | Gastrointestina... Unresectable So... Recurrent Metas... | 18 Years - | First Affiliated Hospital, Sun Yat-Sen University | ||
| Avapritinib in CBF-AML With KIT Mutations | NCT05821738 | Core Binding Fa... KIT Mutation-Re... | Avapritinib | 15 Years - | The First Affiliated Hospital of Soochow University | |
| A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors | NCT05464875 | Gastrointestina... Unresectable So... Recurrent Metas... | 18 Years - | First Affiliated Hospital, Sun Yat-Sen University | ||
| Expanded Access Program for Avapritinib | NCT04714086 | Solid Tumors | Avapritinib | 18 Years - | Blueprint Medicines Corporation | |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | NCT03731260 | Indolent System... | Avapritinib Placebo | 18 Years - | Blueprint Medicines Corporation | |
| (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | NCT02508532 | Gastrointestina... Other Relapsed ... | Avapritinib | 18 Years - | Blueprint Medicines Corporation | |
| Avapritinib in CBF-AML With KIT Mutations | NCT05821738 | Core Binding Fa... KIT Mutation-Re... | Avapritinib | 15 Years - | The First Affiliated Hospital of Soochow University | |
| (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | NCT02561988 | Aggressive Syst... Systemic Mastoc... Mast Cell Leuke... Relapsed or Ref... | Avapritinib | 18 Years - | Blueprint Medicines Corporation | |
| Expanded Access Program for Avapritinib | NCT04714086 | Solid Tumors | Avapritinib | 18 Years - | Blueprint Medicines Corporation | |
| (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | NCT03465722 | GIST | avapritinib regorafenib | 18 Years - | Blueprint Medicines Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
